Institute for Cell and Tumor Biology
About the Schneider Lab
Welcome to the Schneider Lab, a vibrant hub of scientific inquiry and innovation nestled within the Department of Developmental Biology at Erasmus MC, Rotterdam, and the Institute for Cell and Tumor Biology, Uniklinik RWTH Aachen. Visit our dedicated portal at schneiderlab.org to learn more about our exciting work.
At the Schneider Lab, we are driven by a profound commitment to understanding and combating clonal myeloid neoplasms. Through a multidisciplinary approach that spans genomics, proteomics, CRISPR Cas9 gene editing, and advanced 3D cell-culture modeling, our research delves into the complex regulation of hematopoietic stem cells in myeloid malignancies. Our mission is clear: to identify and validate novel therapeutic targets capable of eradicating disease-initiating cells and transforming patient outcomes.
Our team thrives in an open, friendly, and diverse international environment, fostering collaboration across borders and disciplines. We utilize cutting-edge technologies, including various single-cell genomic tools and transgenic mouse models, to unravel the cellular and molecular mechanisms underpinning disease. This concerted effort enables us to explore innovative treatment strategies and bring forth groundbreaking discoveries, such as our work on the cellular drivers of bone marrow fibrosis and the regulation of hematopoietic stem cells in del(5q) MDS.
Direktorin
Kontakt
Uniklinik RWTH Aachen
Pauwelsstrasse 30
D-52074 Aachen
Sekretariat
Eveline Mierau
Tel.:
+49 241 80-80760 (Büro)
+49 241 80-80759 (Sekretariat)
Fax: +49 241 80-82008
eveline.mieraurwth-aachende
Standort: Uniklinik RWTH Aachen, Etage -1, D1-D2, Raum 5
New findings on the role of the Hedgehog signaling pathway in myeloproliferative neoplasms
Researchers have made significant progress in understanding myeloproliferative neoplasms (MPNs), a group of blood diseases characterized by the excessive production of blood cells. Specifically, they…
New treatment options discovered for del(5q) myelodysplastic syndrome
A research team led by Prof. Dr. Schneider-Kramann has made significant advancements in understanding the del(5q) Myelodysplastic Syndrome (MDS), a blood disorder characterized by the deletion of part…
Im Kampf gegen Fibrose im Knochenmark: Prof. Rebekka Schneider-Kramann erhält ERC Consolidator Grant
Rebekka Schneider-Kramanns Forschung ist ein Kampf – gegen die Fibrose. So nennt es die Professorin für Zellbiologie an der RWTH Aachen und Direktorin des Instituts für Zell- und Tumorbiologie an der…
